Results 71 to 80 of about 13,988 (233)

In‐hospital mortality in gastroparesis population and its predictors: A United States‐based population study

JGH Open, 2021
Background and Aim To determine the United States‐based in‐hospital gastroparesis mortality rate and independent predictors associated with it. Methods A retrospective study was conducted using the deidentified National Inpatient Sample and Healthcare ...
Saad Saleem, Faisal Inayat, Muhammad Aziz, Eric O Then, Yousaf Zafar, Vinaya Gaduputi   +5 more
doaj   +1 more source

In reply: Gastroparesis

Cleveland Clinic Journal of Medicine, 2019
In Reply: We thank the readers for their letter. Our patient’s laboratory values at the time of presentation were as follows: The rest of the electrolyte levels were within normal limits. These reported electrolyte levels were unlikely to cause such gastroparesis.
Ahmad Muneer, Sharayah, Noor, Hajjaj, Ramy, Osman, Douglas, Livornese   +3 more
openaire   +2 more sources

Psychological research in eating disorders/disordered eating in type 1 diabetes: A systematic review using the NIH stage model for behavioural intervention development

Diabetic Medicine, EarlyView.
Abstract Aims Eating disorders in type 1 diabetes are 2.4 times more likely to develop than those who do not have diabetes. The aim was to conduct a systematic review on psychological interventions in IRDEB (insulin‐related disordered eating behaviour)/eating disorders with adults who have type 1 diabetes.
Heather L. Stuckey, Debbie Cooke, Amy C. Knehans, Timothy C. Skinner   +3 more
wiley   +1 more source

Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy – a retrospective cohort study

BMJ Open Gastroenterology
Objective The use of glucagon-like peptide 1 receptor agonists has been associated with gastroparesis, but little is known about the risk of gastroparesis in those with obesity but without type 2 diabetes (T2D), and how that risk compares with other ...
Feibi Zheng, Elizabeth Wall-Wieler, Reem Z Sharaiha, Chino Aneke-Nash, Kay Su Hung   +4 more
doaj   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Mirtazapine for symptom control in refractory gastroparesis

, 2017
Mark Malamood,1 Aaron Roberts,2 Rahul Kataria,2 Henry P Parkman,2 Ron Schey2 1Department of Internal Medicine, 2Department of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA Introduction: Gastroparesis symptoms can be severe and ...
Schey R, Parkman HP, Roberts A, Kataria R, Malamood M   +4 more
core  

Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis

Gut and Liver, 2020
Background/Aims: Ghrelin agonists are emerging prokinetic agents for treating gastroparesis. Although recent clinical trials have demonstrated their efficacy in patients with diabetic gastroparesis (DG), the impact of such agents on symptoms and gastric ...
Seung Wook Hong, Jaeyoung Chun, Jihye Kim, Jooyoung Lee, Hyun Jung Lee, Hyunsoo Chung, Soo-Jeong Cho, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim   +9 more
doaj   +1 more source

Prevalence of Hidden Gastroparesis in the Community: The Gastroparesis "Iceberg"

Journal of Neurogastroenterology and Motility, 2012
The prevalence of diagnosed gastroparesis is 24.2/100,000 inhabitants, but a large group of people with gastroparesis-like symptoms have never had a gastric emptying (GE) test. Some of them may have undiagnosed gastroparesis. Our aim was to estimate the prevalence of hidden gastroparesis in the community.The study was conducted in 2 parts: (1) Patients
Rey, Enrique, Choung, Rok Seon, Schleck, Cathy D., Zinsmeister, Alan R., Talley, Nicholas J., Locke III, G. Richard   +5 more
openaire   +3 more sources

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source

Gastroparesis: a review of current and emerging treatment options

, 2013
Chijioke Enweluzo, Fahad AzizHospital Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, USAAbstract: Gastroparesis is a motility disorder of the stomach causing delay in food emptying from the stomach without ...
Enweluzo C, Aziz F
core